ORGANIZACION DEL PROGRAMA DE VACUNACION UNIVERSAL FRENTE A HEPATITIS B EN ESCOLARES Y COBERTURA DEL PRIMER AÑO DE VACUNACION. EXTREMADURA

This paper studies the proportion of the population reached by the programme of universal vaccination against Hepatitis B for children of 13 during the first year since its introduction in Extremadura (Spain). A reach of 96.04% is considered satisfactory and higher than that achieved in other pilot programmes, and even higher than that of other childhood vaccines. This is attributed to the energetic organization of the progmmme within those activities aimed at children of school age, to the information and participation by the various social and institutional bodies involved, to the work of the Extremaduran Health Education Board, and to the ongoing work of teams of health workers and doctors. There are no signiticant differences between urban and rural Health Clinics. These differences are to be found in those areas where the aforementioned teams and the traditional model have begun to operate. Given the existing health system in this country and the widespread nature of the illness, it is assumed that the most effective method of vaccination would be that aimed at the high-risk population, the children of mothers who are carriers, and universal vaccination of school-age children.

[1]  A. G. Ortiz,et al.  ESTUDIO SEROEPIDEMIOLOGICO Y PROGRAMA DE VACUNACION FRENTE A LA HEPATITIS B EN ESCOLARES. EXTREMADURA , 2008 .

[2]  T. Pumarola,et al.  Prevalence of hepatitis B markers in the population of catalonia (Spain). Rationale for universal vaccination of adolescents , 1992, European Journal of Epidemiology.

[3]  M. Burgess Hepatitis B in urban Australian school children , 1994 .

[4]  M. Burgess,et al.  Hepatitis B in urban Australian schoolchildren , 1993, The Medical journal of Australia.

[5]  A J Hall,et al.  The influence of age on the development of the hepatitis B carrier state , 1993, Proceedings of the Royal Society of London. Series B: Biological Sciences.

[6]  M. Lindegren,et al.  Evaluation of telephoned computer-generated reminders to improve immunization coverage at inner-city clinics. , 1993, Public health reports.

[7]  M. KindelánRecarte,et al.  The vaccination coverage in a cohort of children at 2 years of age from a health area , 1993 .

[8]  N. Halsey Discussion of Immunization Practices Advisory Committee/American Academy of Pediatrics recommendations for universal infant hepatitis B vaccination. , 1993, The Pediatric infectious disease journal.

[9]  D. Greenberg Pediatric experience with recombinant hepatitis B vaccines and relevant safety and immunogenicity studies. , 1993, The Pediatric infectious disease journal.

[10]  H. Inskip,et al.  Efficacy of hepatitis B vaccine in the Gambian expanded programme on immunisation , 1993, The Lancet.

[11]  B. Bloom,et al.  A Reappraisal of Hepatitis B Virus Vaccination Strategies Using Cost-Effectiveness Analysis , 1993, Annals of Internal Medicine.

[12]  A. Detsky,et al.  Should Canada and the United States Universally Vaccinate Infants against Hepatitis B? , 1993, Medical decision making : an international journal of the Society for Medical Decision Making.

[13]  F. Salvá,et al.  A 7-year follow-up of newborns vaccinated against hepatitis B. , 1993, Vaccine.

[14]  G. Calandra,et al.  Control of hepatitis B through routine immunization of infants: the need for flexible schedules and new combination vaccine formulations. , 1993, Vaccine.

[15]  D. Coetzee,et al.  A vaccination survey using the EPI methodology ot evaluate the impact of a child health outreach programme in an urban area of South Africa. , 1993, Bulletin of the World Health Organization.

[16]  S. Berger,et al.  Cost-benefit analysis of a nationwide inoculation programme against viral hepatitis B in an area of intermediate endemicity. , 1992, Bulletin of the World Health Organization.

[17]  Y. Ghendon WHO strategy for the global elimination of new cases of hepatitis B. , 1990, Vaccine.

[18]  E. Dahl-Hansen,et al.  Immunogenicity of yeast-derived hepatitis B vaccine from two different producers , 1990, Epidemiology and Infection.